モノクローナル抗体バイオシミラー開発に対するFDAの第3相免除の純現在価値への影響
Ranjit Ranbhor1, Priyanka Kulkarni2
1Business Development, Portfolio and Patents, Odin Pharmaceuticals LLC, Somerset, NJ, USA.
Biologics : targets & therapy
|February 19, 2026
まとめ
米国FDAは,
科学分野:
- バイオ医薬品開発
- 規制科学 規制科学とは
- 健康経済学 医療経済学
背景:
- 米国食品医薬品局 (FDA) は2025年10月にガイドラインを発行し,バイオシミラルの第3相比較有効性試験を免除することを提案しました.
- 免除は,バイオシミラーと基準製品との間の分析的類似性と薬理学的同等性の証明に条件付けられています.
研究 の 目的:
- 純現在価値 (NPV) 分析を行い,伝統的なバイオシミラー開発経路とフェーズ3の研究を比較し,FDAが提案したフェーズ3の免除枠組みを利用した合理化された経路を比較する.
- バイオシミラー開発コストとタイムラインに関するフェーズ3の研究を放棄した経済的影響を評価する.
主な方法:
- 純現在価値 (NPV) モデルが開発され,第3段階の研究のための業界ベンチマークのコストとタイムラインデータを組み込みました.
- 経済的な成果は,高,中,低複雑性モノクローナル抗体バイオシミラープログラムで評価されました.
- パラメータ変動の影響を評価するために,感度分析が行われました.
主要な成果:
- フェーズ3の研究を放棄すると,開発コストがプログラムあたり平均2500万ドル (18%削減) 削減され,開発のタイムラインが約1.5年 (21%削減) 短縮されると予測されています.
- リスク調整済のNPVは,2500万ドル (29%) 改善され,最低可行ピーク売上高の値が3億ドルから2億5000万ドルに低下すると推定されています.
結論:
- フェーズ3の免除は,FDAの基準を満たす,よく特徴づけられたモノクローナル抗体のバイオシミラルのコスト削減と加速されたタイムラインを含む,実質的な経済的利益を提供します.
- これらの利点の実現は,堅実な分析データ,成功した免除承認,適切な製品選択,およびFDAの承認パターンの実施後の監視に依存しています.
- 経済的な利点は,2026年から2027年の期間から実現すると予想されます.
関連する概念動画
01:28Drug Products: Biologics, Biosimilars and Interchangeables
288
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288
01:13Bioequivalence studies: Biowaivers
292
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
292
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
24
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
24
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
489
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
489
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
322
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
322
01:26FDA Approved Drugs: Changes to Approved Drugs
286
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
286